Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2023-03-17 00:00:00 ET · period of report 2023-03-15 · accession 0001209191-23-019879 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-17 | 2023-03-16 | TARS | Mottiwala Aziz | Chief Commercial Off | S - Sale+OE | $13.43 | -336 | 54.6K | -0.6% | -$4,512 |
| D | 2023-03-17 | 2023-03-15 | TARS | Mottiwala Aziz | Chief Commercial Off | M - OptEx | — | +4,790 | 54.9K | +10% | — |
| D | 2023-03-17 | 2023-03-15 | TARS | Mottiwala Aziz | Chief Commercial Off | M - OptEx | $0.00 | -4,790 | 14.4K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-16 | S | D | 336 | $13.43 | 54,604 | D | — | — | |
| 2 | Common | Common Stock | 2023-03-15 | M | A | 4,790 | — | 54,940 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). (F2) Includes 421 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022. |
| 3 | Derivative | Restricted Stock Units | 2023-03-15 | M | D | 4,790 | $0.00 | 14,370 | D | — · — to — | 4,790 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Company's common stock. (F5) RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. |